SETD2 and nonpapillary renal cell carcinoma: A recent study that performed metabolic profiling of 138 primary ccRCCs showed enhanced fatty acid biosynthesis and reduced oxidative phosphorylation during the early stages of tumorigenesis, which was reversed during disease progression suggesting that a shift in metabolism is linked to and/or necessary for ccRCC progression, consistent with SETD2 loss being associated with ccRCC progression and reduced relapse free survival [6,9,13,14,65].